OUR TEST
THE FIRST BLOOD TEST SPECIFICALLY DESIGNED FOR THE EARLY DETECTION OF STOMACH CANCER.
CORE CONCEPT
GastroMDx is a non-invasive, blood-based diagnostic test developed by Ilico Genetics to detect gastric (stomach) cancer in its earliest stages — often years before traditional methods can identify signs of disease. It represents a breakthrough in early detection technology by allowing clinicians to identify molecular changes long before symptoms appear.
KEY DIFFERENTIATORS
-
Simple blood draw, eliminating the need for endoscopy in early screening phases.
-
Detects early-stage disease (when survival rates are highest) by identifying unique biomarker profiles.
-
Designed to find cancer before physical symptoms appear.
-
Lower cost and minimal discomfort make it feasible for widespread use across at-risk populations.
SCIENTIFIC FOUNDATION
While traditional screening methods like endoscopy are invasive, expensive, and impractical for large-scale population screening, GastroMDx uses molecular biomarkers found in blood to detect the presence or risk of gastric cancer.
These biomarkers are based on genetic and epigenetic signatures — subtle alterations in DNA or RNA expression patterns — that can indicate the early presence of malignancy. The “MDx” suffix stands for Molecular Diagnostics, which places the test in a growing field of precision medicine tools designed to bring laboratory-level insights directly into clinical settings.
Stomach cancer is one of the deadliest cancers worldwide, largely because it’s usually diagnosed too late. By the time symptoms emerge, treatment options are limited and outcomes poor.
GastroMDx directly addresses this gap by bringing early detection to the front line of care — helping physicians act sooner and saving more lives through timely diagnosis.
Only about 14% of all diagnosed cancers in the US are detected through a screening test for which there is a broad recommendation.*
In that same study, approximately 57% of all diagnosed cancers have no broadly-recommended screening test at all, and these account for nearly 70% of US cancer deaths.
Most cancers are still found too late, when treatment options are limited and survival rates drop sharply.
Nearly 70% of cancer deaths come from cancers with no screening test at all.
Only four cancers have standard screening, leaving the majority of patients unprotected.
EARLY DETECTION, EXPLAINED:
Cancer begins long before symptoms appear. In those early stages, abnormal cells are multiplying quietly — often for years — before they grow large enough to cause pain, bleeding, or visible changes. By the time most people notice something is wrong, the disease has already advanced.
Early detection changes that timeline. It focuses on finding the biological signs of cancer — such as genetic mutations, altered proteins, or molecular markers — that appear in the blood well before a tumor forms or spreads. These are the body’s earliest warning signals, invisible to traditional imaging or scopes.
Early detection doesn’t just save time. It saves lives.
With tools like GastroMDx™, physicians can now detect these molecular clues through a single blood draw. It means identifying risk earlier, guiding decisions sooner, and giving patients access to treatment when it has the best chance to succeed.
BACKED BY DATA.
Our pilot study validated GastroMDx™ with 89 patients, demonstrating exceptional diagnostic performance.
The test achieved 99% accuracy, 100% specificity, and 97% sensitivity — confirming its ability to detect early gastric cancer with remarkable precision. These results reinforce GastroMDx’s potential to redefine how stomach cancer is identified and treated, offering a powerful step forward in early detection.
FREQUENTLY ASKED QUESTIONS.
Get clear answers about GastroMDx™, how it works, and what makes early detection possible.
-
Ilico Genetics develops advanced diagnostic technologies that make early cancer detection accessible and precise. Our flagship innovation, GastroMDx™, uses a simple blood test to identify stomach cancer in its earliest stages — years before symptoms typically appear.
-
The test is intended for individuals at higher risk for gastric cancer, such as those with a family history, chronic gastritis, Helicobacter pylori infection, or living in regions where gastric cancer rates are high. Your healthcare provider can help determine if GastroMDx is right for you.
-
In its pilot study of 89 patients, GastroMDx achieved 99% accuracy, 100% specificity, and 97% sensitivity, demonstrating exceptional reliability in detecting early gastric cancer markers.
-
The process is quick and non-invasive — it only requires a standard blood draw. The sample is analyzed in a certified laboratory using Ilico’s proprietary predictive model to identify molecular patterns linked to early-stage gastric cancer.
-
Ilico Genetics is completing regulatory and clinical validation steps to make the test available to healthcare providers. Updates on availability will be shared as the test moves toward broader clinical use.